Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Sorrento Therapeutics (SRNE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGNResearch Report) and Sorrento Therapeutics (SRNEResearch Report).

Amgen (AMGN)

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Amgen, with a price target of $243.00. The company’s shares closed last Tuesday at $246.97.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 6.7% and a 47.3% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Mirati Therapeutics, and Gilead Sciences.

Currently, the analyst consensus on Amgen is a Hold with an average price target of $250.79, a 1.2% upside from current levels. In a report issued on July 7, RBC Capital also maintained a Hold rating on the stock with a $224.00 price target.

See today’s best-performing stocks on TipRanks >>

Sorrento Therapeutics (SRNE)

Dawson James analyst Jason Kolbert maintained a Buy rating on Sorrento Therapeutics on July 8 and set a price target of $16.00. The company’s shares closed last Tuesday at $2.62.

According to TipRanks.com, Kolbert is a 1-star analyst with an average return of -0.7% and a 37.4% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Citius Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sorrento Therapeutics with a $16.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed